Price movement over the last 24 hours
Abeona Therapeutics Inc vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $40.26. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | QDTY | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $7.23 | $46.71 |
52-Week Low | $4.17 | $36.57 |
Enterprise Value | $228.22M | — |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
QDTY trades at $41.16, up 1.66% today, but technical indicators signal a bearish trend with moving averages and overall signals pointing lower. The stock exhibits weekly dividend distributions, with recent payouts ranging from $0.22 to $0.32. Support and resistance levels are clustered near the current price, indicating potential volatility. Recent news focuses heavily on dividend announcements from YieldMax ETFs, with minimal coverage of broader business performance or financial results.
The outlook remains cautious due to weak technical momentum and lack of fundamental data. Investment opportunity hinges on dividend yield sustainability, but risks include absence of earnings visibility and bearish technical pressure. Key catalysts for reversal would require positive earnings surprises or upward analyst revisions, which are currently unavailable.
Trailing returns across standard periods
Latest headlines on both assets
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.
Read more on QDTY →